• Drug Des Dev Ther · Jan 2021

    Review

    Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.

    • Mohamad Moussa, Athanasios Papatsoris, Abou ChakraMohamedMDepartment of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon., and Athanasios Dellis.
    • Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon.
    • Drug Des Dev Ther. 2021 Jan 1; 15: 453-462.

    AbstractNowadays the therapeutic landscape for advanced and metastatic urothelial carcinoma continues to evolve. The recent regulatory approval of enfortumab vedotin (EV) for the treatment of advanced urothelial cancer confirms the evolving role of antibody-drug conjugates. EV demonstrates a favorable profile in heavily pretreated patients with locally advanced or metastatic urothelial carcinoma. Early survival reports demonstrate a significant antitumor effectiveness along with a rather acceptable safety profile in a difficult-to-treat population.© 2021 Moussa et al.

      Pubmed     Free full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…